Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T22:15:46.273Z.
Calculation as of: 2026-10-06T22:15:46.273Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f9f7ef7d03019e78f4201474ef0c74f9c2a497de6c29d743f28e52983e243880
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$2.99B
PE Ratio
114.72
TTM Avg
121.55
3Y Avg
121.55
5Y Avg
121.55
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | $3.12B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | N/A | 239.54 | 239.54 | 239.54 |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | N/A | N/A | N/A | N/A |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.03B | N/A | N/A | N/A | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 114.72 | 121.55 | 121.55 | 121.55 |
| CareDx, Inc (CDNA)vs › | $3.30B | 30.80 | 18.61 | 17.43 | 17.43 |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | N/A | N/A | N/A | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | N/A | N/A | N/A | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 8.89 | 12.92 | 23.68 | 23.68 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$28.04
Forward EPS (Est.)
$-1.51
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2024-05-09 | 2.70 |
| 2024-05-08 | 2.75 |
| 2024-05-07 | 2.81 |
| 2024-05-06 | 2.84 |
| 2024-05-03 | 2.90 |
| 2024-05-02 | 2.85 |
| 2024-05-01 | 2.75 |
| 2024-04-30 | 2.58 |
| 2024-04-29 | 2.71 |
| 2024-04-26 | 2.51 |
| 2024-04-25 | 2.54 |
| 2024-04-24 | 2.68 |
| 2024-04-23 | 2.78 |
| 2024-04-22 | 2.83 |
| 2024-04-19 | 2.67 |
| 2024-04-18 | 2.83 |
| 2024-04-17 | 2.85 |
| 2024-04-16 | 2.87 |
| 2024-04-15 | 2.95 |
| 2024-04-12 | 3.00 |
| 2024-04-11 | 3.27 |
| 2024-04-10 | 3.51 |
| 2024-04-09 | 3.81 |
| 2024-04-08 | 3.84 |
| 2024-04-05 | 3.74 |
| 2024-04-04 | 3.73 |
| 2024-04-03 | 3.75 |
| 2024-04-02 | 3.74 |
| 2024-04-01 | 3.87 |
| 2024-03-28 | 4.05 |
| 2024-03-27 | 4.11 |
| 2024-03-26 | 3.91 |
| 2024-03-25 | 3.87 |
| 2024-03-22 | 3.91 |
| 2024-03-21 | 4.10 |
| 2024-03-20 | 4.24 |
| 2024-03-19 | 4.18 |
| 2024-03-18 | 4.08 |
| 2024-03-15 | 4.62 |
| 2024-03-14 | 4.52 |
| 2024-03-13 | 4.91 |
| 2024-03-12 | 4.91 |
| 2024-03-11 | 5.42 |
| 2024-03-08 | 4.80 |
| 2024-03-07 | 27.08 |
| 2024-03-06 | 27.19 |
| 2024-03-05 | 26.91 |
| 2024-03-04 | 27.32 |
| 2024-03-01 | 26.71 |
| 2024-02-29 | 26.91 |
| 2024-02-28 | 27.93 |
| 2024-02-27 | 27.12 |
| 2024-02-26 | 25.06 |
| 2024-02-23 | 25.19 |
